Cargando…

Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate

Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a hypercoagulable status. There is limited knowledge regarding the dynamic changes in coagulation factors among COVID-19 patients on nafamostat mesylate, a potential therapeutic anticoagulant for COVID-19. Fir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osawa, Itsuki, Okamoto, Koh, Ikeda, Mahoko, Otani, Amato, Wakimoto, Yuji, Yamashita, Marie, Shinohara, Takayuki, Kanno, Yoshiaki, Jubishi, Daisuke, Kurano, Makoto, Harada, Sohei, Okugawa, Shu, Yatomi, Yutaka, Moriya, Kyoji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486975/ https://www.ncbi.nlm.nih.gov/pubmed/32920751 http://dx.doi.org/10.1007/s11239-020-02275-5

Ejemplares similares

Clot waveform of APTT has abnormal patterns in subjects with COVID-19
por: Shimura, Takuya, et al.
Publicado: (2021)

Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries
por: Morita, Yoshifumi, et al.
Publicado: (2022)

Plesiomonas shigelloides Septic Shock Following Ingestion of Dojo Nabe (Loach Hotpot)
por: Shinohara, Takayuki, et al.
Publicado: (2021)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

90. Incidence and Risk Factors for Inappropriate Use of Non-culture Based Fungal Assays: Implication for Diagnostic Stewardship
por: Ito, Hiroshi, et al.
Publicado: (2020)

Incidence and Risk Factors for Inappropriate Use of Non-Culture-Based Fungal Assays: Implication for Diagnostic Stewardship
por: Ito, Hiroshi, et al.
Publicado: (2021)

The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study
por: Jubishi, Daisuke, et al.
Publicado: (2022)

Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination
por: Ishii, Takashi, et al.
Publicado: (2023)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Dynamic modulations of sphingolipids and glycerophospholipids in COVID‐19
por: Kurano, Makoto, et al.
Publicado: (2022)

Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries
por: Kurano, Makoto, et al.
Publicado: (2022)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)

Protothecosis in the mucosa of the pharynx mimicking pharyngeal cancer in an immunocompetent individual: a case report
por: Yamashita, Marie, et al.
Publicado: (2022)

Cytokine expressions of spinal cord injury treated by neurotropin and nafamostat mesylate
por: Sun, Chao, et al.
Publicado: (2021)

Increase in serum levels of phosphatidylserine-specific phospholipase A(1) in COVID-19 patients
por: Shimura, Takuya, et al.
Publicado: (2021)

Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples
por: Mizoguchi, Miyuki, et al.
Publicado: (2021)

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
por: Hernández-Mitre, María Patricia, et al.
Publicado: (2022)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023)

Decrease in serum levels of autotaxin in COVID-19 patients
por: Shimura, Takuya, et al.
Publicado: (2022)

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
por: Okajima, Masaki, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Anaphylactic Reactions Caused by Nafamostat Mesylate during Hemodialysis before Surgery for Carpal Tunnel Syndrome
por: Nakamura, Yuta, et al.
Publicado: (2021)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
por: Kim, Hyeon-A, et al.
Publicado: (2022)

Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition
por: Morimoto, Mari, et al.
Publicado: (2022)

Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
por: Ikeda, Mahoko, et al.
Publicado: (2015)

Clinical Features of Bloodstream Infections Associated with Peripheral Versus Central Venous Catheters
por: Tatsuno, Keita, et al.
Publicado: (2019)

Clinical and Microbiological Characteristics of Recurrent Escherichia coli Bacteremia
por: Kobayashi, Tatsuya, et al.
Publicado: (2021)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
por: Ikeda, Mahoko, et al.
Publicado: (2021)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
por: Hirayama, Takahiro, et al.
Publicado: (2017)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
por: Zhang, Yuxin, et al.
Publicado: (2020)

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
por: Chen, Xi, et al.
Publicado: (2019)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional Study
por: Yokoyama, Rin, et al.
Publicado: (2021)

Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis
por: Inman, Robert D, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_h618l9k3gd972iaqb4p84ph43a